A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

Also called NCT01388816

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 176 participants (enrolled count) (from the registry)
Sponsor
Dr. Reddy's Laboratories Limited, India (from the registry)
Registry
  • NCT NCT01388816
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Italy, Poland, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01388816. Randomized; quadruple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2014-04-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
Condition
Type II Hyperlipidemia
Intervention (Drug)
DRL-17822 or placebo
Lead sponsor
Dr. Reddy's Laboratories Limited, India (class: industry)
Collaborator
PharmaNet (class: industry)

Record details

Record id
cardio:ct-nct01388816
Content hash
24afa218eca39e0689e69b2a4360cecba842b068d8929aafb90ff261f9cb6de1